Substituted pyrazin-2-amines as inhibitors of ATR kinase

Patent metadata

Field	Value
Publication number	US-10479784-B2
Application number	US-201815967110-A
Country	US
Kind code	B2
Filing date	Apr 30, 2018
Priority date	Dec 19, 2008
Publication date	Nov 19, 2019
Grant date	Nov 19, 2019

Abstract

The present invention relates to pyrazine compounds useful as inhibitors of ATR protein kinase. The invention also relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and methods of using the compounds in in vitro applications, such as the study of kinases in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such kinases; and the comparative evaluation of new kinase inhibitors.
The compounds of this invention have formula I:

wherein the variables are as defined herein.

First claim

We claim:

1. A compound selected from the group consisting of:

or a pharmaceutically acceptable salt thereof.

2. The compound of claim 1 , wherein the compound is:

or a pharmaceutically acceptable salt thereof.

3. The compound of claim 1 , wherein the compound is:

or a pharmaceutically acceptable salt thereof.

4. The compound of claim 1 , wherein the compound is:

or a pharmaceutically acceptable salt thereof.

5. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of claim 1 , or a pharmaceutically acceptable salt thereof.

6. A method of sensitizing a cancer cell in a patient to a DNA damaging agent, comprising administering to a patient in need thereof an effective amount of the compound of claim 1 .

7. The method of claim 6 , wherein the cancer cell expresses a DNA damaging oncogene.

8. The method of claim 7 , wherein the cancer cell has altered expression or activity of one or more proteins selected from the group consisting of K-Ras, N-Ras, H-Ras, Raf, Myc, Mos, E2F, Cdc25A, CDC4, CDK2, Cyclin E, Cyclin A and Rb.

9. The method of claim 6 , wherein the cancer cell has a defect in ataxia telangiectasia mutated signaling cascade.

10. The method of claim 9 , wherein the defect is altered expression or activity of one or more proteins selected from the group consisting of ataxia telangiectasia mutated, p53, checkpoint kinase 2, MRE11, RAD50, NBS1, 53BP1, MDC1 and H2AX.

Assignees

• Vertex Pharma

Inventors

• Charrier Jean-Damien
• Durrant Steven John
• Kay David
• Knegtel Ronald Marcellus Alphonsus
• Maccormick Somhairle
• Mortimore Michael Paul
• O'Donnell Michael Edward
• Pinder Joanne
• Rutherford Alistair
• Virani Anisa Nizarali
• Young Stephen Clinton
• Reaper Philip Michael

Classifications

• C07D417/14

  containing three or more hetero rings · CPC title

• C07D401/04

  directly linked by a ring-member-to-ring-member bond · CPC title

• C07D403/12

  linked by a chain containing hetero atoms as chain links · CPC title

• C07D401/10

  linked by a carbon chain containing aromatic rings · CPC title

• C07D471/04

  Ortho-condensed systems · CPC title